For the quarter ending 2026-03-31, CLRB had -$4,848,943 decrease in cash & cash equivalents over the period. -$4,848,943 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Change in operating lease right-of-use asset | - | 20,169 | 19,407 | 36,626 |
| Net loss | -5,653,946 | -5,295,221 | -4,443,876 | -12,051,940 |
| Depreciation and amortization | -110,018 | 49,461 | 52,277 | 111,859 |
| Stock-based compensation expense | 451,869 | 567,788 | 567,788 | 1,128,128 |
| Change in operating lease right-of-use asset | -3,246 | - | - | - |
| Change in fair value of warrants | -77,000 | -297,833 | -294,276 | -161,598 |
| Prepaid expenses and other current assets | -245,498 | -224,977 | -509,170 | 614,914 |
| Lease liability | - | -22,343 | -21,580 | -40,494 |
| Accounts payable and accrued liabilities | 301,278 | 408,866 | -664,031 | -2,906,627 |
| Cash used in operating activities | -4,845,565 | -4,344,136 | -4,275,121 | -14,498,960 |
| Purchases of property, plant & equipment | 3,378 | 5,880 | - | - |
| Cash used in investing activities | -3,378 | -5,880 | - | - |
| Proceeds from exercise of warrants, net of issuance costs (note 2) | - | - | 0 | 2,251,380 |
| Proceeds from exercise of warrants and new warrants, net of issuance costs | - | 7,243,140 | 3 | - |
| Proceeds from issuance of common stock, pre-funded warrants and common warrants, net of issuance costs | - | 0 | 5,788,380 | - |
| Cash provided by financing activities | - | 4,991,760 | 5,788,383 | 2,251,380 |
| Net (decrease) increase in cash and cash equivalents | -4,848,943 | 641,744 | 1,513,262 | -12,247,580 |
| Cash and cash equivalents at beginning of period | 13,196,033 | 12,554,289 | 23,288,607 | - |
| Cash and cash equivalents at end of period | 8,347,090 | 13,196,033 | 12,554,289 | - |
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)